Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01736462 · ClinicalTrials.gov registry record · Phase 1
Corneal Endothelial Cell Density Changes, When Mapracorat Ophthalmic Suspension 3%, is Administered for 14 Days
A Phase 1 study, sponsored by Bausch & Lomb Incorporated.
- Completed
- Registry status
- Phase 1
- Development phase
- 61
- Enrollment target
NCT01736462 is a Phase 1 study that has completed, run by Bausch & Lomb Incorporated. The registered enrollment target is 61 participants.
The verdict
NCT01736462, a Phase 1 study, has completed, sponsored by Bausch & Lomb Incorporated.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 61 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate the effect on corneal endothelial cell density (cells/mm²) changes at 3 months when mapracorat ophthalmic suspension, 3% is administered QID (four times daily), for 14 days in healthy subjects with a normal ophthalmic history.
Interventions
- DRUG Mapracorat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2013-02 |
| Est. Completion | 2013-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01736462
The ClinicalTrials.gov registry entry for NCT01736462 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bausch & Lomb Incorporated, which has 174 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Mapracorat is the first listed.
NCT01736462 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01736462 about?
NCT01736462 is a clinical study titled "Corneal Endothelial Cell Density Changes, When Mapracorat Ophthalmic Suspension 3%, is Administered for 14 Days". The objective of this study is to evaluate the effect on corneal endothelial cell density (cells/mm²) changes at 3 months when mapracorat ophthalmic suspension, 3% is administered QID (four times daily), for 14 days in healthy subjects with a normal ophthalmic history.
What is the current status of trial NCT01736462?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 61 participants. The study started on 2013-02. Estimated completion is 2013-07.
What interventions are being tested in trial NCT01736462?
The interventions under investigation include: Mapracorat (DRUG).
Who is sponsoring clinical trial NCT01736462?
This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.